1ST Bio Bets On BBB-Penetrating C-ABL Inhibitor As Potential Disease-Modifying Parkinson's Drug
Emerging Company Profile: 1ST Biotherapeutics CEO highlights its lead candidate program – a novel small molecule c-Abl inhibitor, which touts superior blood-brain penetration and selectivity – for its potential to become a disease-modifying drug for Parkinson's disease.
You may also be interested in...
Denmark's mid-sized biopharma, Lundbeck, has taken another potential Parkinson's disease therapeutic into early clinical studies, the third this year, and this time it's a monoclonal antibody, not a small molecule.
Private Company Edition: Gossamer, Ascentage and Alector continued the trend of large venture capital rounds, recently raising $230m, $150m and $133m, respectively. Led by former Receptos executives, Gossamer has multiple clinical trials planned, but continues to keep details of its drug candidates under wraps.
GemVax unveils positive topline results for South Korean Phase II study of novel peptide drug targeting patients with moderate to severe Alzheimer’s disease, raising hopes for the upcoming US trials.